CYP1A1

Jump to navigation Jump to search

Template:PBB

WikiDoc Resources for CYP1A1

Articles

Most recent articles on CYP1A1

Most cited articles on CYP1A1

Review articles on CYP1A1

Articles on CYP1A1 in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on CYP1A1

Images of CYP1A1

Photos of CYP1A1

Podcasts & MP3s on CYP1A1

Videos on CYP1A1

Evidence Based Medicine

Cochrane Collaboration on CYP1A1

Bandolier on CYP1A1

TRIP on CYP1A1

Clinical Trials

Ongoing Trials on CYP1A1 at Clinical Trials.gov

Trial results on CYP1A1

Clinical Trials on CYP1A1 at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on CYP1A1

NICE Guidance on CYP1A1

NHS PRODIGY Guidance

FDA on CYP1A1

CDC on CYP1A1

Books

Books on CYP1A1

News

CYP1A1 in the news

Be alerted to news on CYP1A1

News trends on CYP1A1

Commentary

Blogs on CYP1A1

Definitions

Definitions of CYP1A1

Patient Resources / Community

Patient resources on CYP1A1

Discussion groups on CYP1A1

Patient Handouts on CYP1A1

Directions to Hospitals Treating CYP1A1

Risk calculators and risk factors for CYP1A1

Healthcare Provider Resources

Symptoms of CYP1A1

Causes & Risk Factors for CYP1A1

Diagnostic studies for CYP1A1

Treatment of CYP1A1

Continuing Medical Education (CME)

CME Programs on CYP1A1

International

CYP1A1 en Espanol

CYP1A1 en Francais

Business

CYP1A1 in the Marketplace

Patents on CYP1A1

Experimental / Informatics

List of terms related to CYP1A1


Cytochrome P450, family 1, subfamily A, polypeptide 1 is a protein[1] which in humans in encoded by the CYP1A1 gene.[2] The protein a member of the cytochrome P450 superfamily of enzymes.[3]

Function

CYP1A1 is involved in phase I xenobiotic and drug metabolism (one substrate of it is theophylline). It is inhibited by fluoroquinolones and macrolides and induced by aromatic hydrocarbons.[4]

CYP1A1 is also known as AHH (aryl hydrocarbon hydroxylase). It is involved in the metabolic activation of aromatic hydrocarbons (polycyclic aromatic hydrocarbons, PAH), for example, benzopyrene (BP), by transforming it to an epoxide. In this reaction, the oxidation of benzo[a]pyrene is catalysed by CYP1A1 to form BP-7,8-epoxide, which can be further oxidized by epoxide hydrolase (EH) to form BP-7,8-dihydrodiol. Finally CYP1A1 catalyses this intermediate to form BP-7,8-dihydrodiol-9,10-epoxide, which is the ultimate carcinogen.[4]

Regulation

The expression of the CYP1A1 and CYP1B1 genes are regulated by the aryl hydrocarbon receptor, a ligand activated transcription factor.[5]

Polymorphisms

Several polymorphisms have been identified in CYP1A1, some of which lead to more highly inducible AHH activity. CYP1A1 polymorphisms include:[6][7][8][9]

  • M1, TC substitution at nucleotide 3801 in the 3'-non-coding region
  • M2, AG substitution at nucleotide 2455 leading to an amino acid change of isoleucine to valine at codon 462
  • M3, TC substitution at nucleotide 3205 in the 3'-non-coding region
  • M4, CA substitution at nucleotide 2453 leading to an amino acid change of threonine to asparagine at codon 461

References

  1. Kawajiri K (1999). "CYP1A1". IARC scientific publications (148): 159–72. PMID 10493257.
  2. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics. 14 (1): 1–18. PMID 15128046. Unknown parameter |month= ignored (help)
  3. Smith G, Stubbins MJ, Harries LW, Wolf CR (1998). "Molecular genetics of the human cytochrome P450 monooxygenase superfamily". Xenobiotica; the fate of foreign compounds in biological systems. 28 (12): 1129–65. PMID 9890157. Unknown parameter |month= ignored (help)
  4. 4.0 4.1 Beresford AP (1993). "CYP1A1: friend or foe?". Drug metabolism reviews. 25 (4): 503–17. PMID 8313840.
  5. Ma Q, Lu AY (2007). "CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies". Drug metabolism and disposition: the biological fate of chemicals. 35 (7): 1009–16. doi:10.1124/dmd.107.015826. PMID 17431034. Unknown parameter |month= ignored (help)
  6. Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, Nebert DW (1991). "Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP". American journal of human genetics. 48 (4): 720–5. PMC 1682951. PMID 1707592. Unknown parameter |month= ignored (help)
  7. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S (1993). "Relationship between genotype and function of the human CYP1A1 gene". Journal of toxicology and environmental health. 40 (2–3): 309–16. PMID 7901425.
  8. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, Garte SJ (1994). "Functional significance of different human CYP1A1 genotypes". Carcinogenesis. 15 (12): 2961–3. PMID 8001264. Unknown parameter |month= ignored (help)
  9. Kiyohara C, Hirohata T, Inutsuka S (1996). "The relationship between aryl hydrocarbon hydroxylase and polymorphisms of the CYP1A1 gene". Japanese journal of cancer research : Gann. 87 (1): 18–24. PMID 8609043. Unknown parameter |month= ignored (help)

Further reading

  • Nelson DR, Zeldin DC, Hoffman SM; et al. (2004). "Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants". Pharmacogenetics. 14 (1): 1–18. PMID 15128046.
  • Masson LF, Sharp L, Cotton SC, Little J (2005). "Cytochrome P-450 1A1 gene polymorphisms and risk of breast cancer: a HuGE review". Am. J. Epidemiol. 161 (10): 901–15. doi:10.1093/aje/kwi121. PMID 15870154.
  • Hildebrandt AG, Schwarz D, Krusekopf S; et al. (2007). "Recalling P446. P4501A1 (CYP1A1) opting for clinical application". Drug Metab. Rev. 39 (2–3): 323–41. doi:10.1080/03602530701498026. PMID 17786624.


it:CYP1A1

Template:WH Template:WS